VALUE ASSESSMENT FRAMEWORKS IN AN ERA OF PERSONALIZED MEDICINE: SHARED OBJECTIVES OR IRRECONCILABLE DIFFERENCES?

Kristen Migliaccio-Walle
Director, GHEOR

May 23, 2018

Panel

Daniel A. Ollendorf, PhD
Chief Scientific Officer
Institute for Clinical and Economic Review (ICER)

Robert W. Dubois, MD, PhD
Chief Science Officer and Executive Vice President
National Pharmaceutical Council (NPC)

Sara Traigle van Geertruyden, JD
Executive Director
Partnership to Improve Patient Care (PIPC)
Disclosure

- No funding was received for the preparation of this Issues Panel

Value Assessment Landscape
Personalized medicine, also called precision or individualized medicine, is an evolving field in which physicians use diagnostic tests to identify specific biological markers, often genetic, that help determine which medical treatments and procedures will work best for each patient.

Barriers to utilization and value demonstration for personalized medicines

<table>
<thead>
<tr>
<th>Knowledge and Empowerment</th>
<th>Lack of education and awareness among patients and health care professionals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lack of patient empowerment</td>
</tr>
<tr>
<td>Value Demonstration</td>
<td>Lack of value recognition (both clinical and economic) and evidence requirements for coverage</td>
</tr>
<tr>
<td></td>
<td>Uncertain evidence requirements for coverage/reimbursement and other access hurdles</td>
</tr>
<tr>
<td></td>
<td>Access and reimbursement hurdles</td>
</tr>
<tr>
<td>Infrastructure</td>
<td>Lack of effective health care delivery infrastructure and information management systems</td>
</tr>
</tbody>
</table>
Value assessment frameworks have the potential to encourage the use of personalized medicine, but that can only happen if frameworks incorporate the elements of personalized medicine that demonstrate its value.

Necessary Considerations for Valuing Personalized Medicines

- Incorporation of Diagnostic Testing
- Heterogeneity of Treatment Effects
- Emerging or Evolving Value Elements
- Individual Values and Circumstance
- Treatment Efficiency
The question is…

**SHARED OBJECTIVES**

- Personalized Medicine
- Value Assessment

OR

- Personalized Medicine
- Value Assessment

**IRRECONCILABLE DIFFERENCES?**

Thank you

Kristen Migliaccio-Walle
kristen.migliaccio@xcenda.com

Daniel A. Ollendorf
dollendorf@icer-review.org

Robert W. Dubois
rdubois@npcnow.org

Sara Traigle van Geertruyden
sara@pipcpatients.org
Where knowledge, reach and partnership shape healthcare delivery.